Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Former Hikma Chief Olafsson Takes Lead At Mallinckrodt

As Teva Names New Global R&D And Chief Medical Officer

Executive Summary

Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.

You may also be interested in...



Hikma Names Injectables Chief Mishlawi As CEO

Hikma’s president of injectables, Riad Mishlawi, has been chosen to become the firm’s new CEO from the start of September. The move comes after a period of success in injectables for Hikma, at the same time as the firm attempts to revive the fortunes of its generics business.

Hikma Could Consider Exit Strategy For Generics Business

Hikma says all options are on the table for its beleaguered generics business, with an immediate sale unlikely but the door open for a longer-term exit strategy. Meanwhile, the firm has also offered an update on recruitment for a new CEO.

2022 Hires Reflect Global Challenges And Opportunities

Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel